Dr Topp speaks with ecancer at the 2017 ASH annual meeting about safety and preliminary anti-tumour activity of the anti-PD-1 monoclonal antibody REGN2810 alone or in combination with REGN1979 in patients with B-lymphoid malignancies.
He discusses the construction and current clinical utility of BiTE therapies, detailing the dose escalation studies of a novel anti-CD20 x anti-CD3 bispecific antibody, and notes the tolerability as assessed by MRD status.
Combination REGN2810 with REGN1979 has been well tolerated, and evaluation of the combination with higher REGN1979 doses continues.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.